In a sensational lawsuit, a former Mallinckrodt (MNK) employee claims that she was fired for repeatedly warning the drug maker about a host of allegedly illegal activities designed to boost sales of a key drug.
Those practices included running a “sham” patient assistance program and refusing to provide payers with clinical data that would be used for making coverage decisions. Moreover, executives were allegedly unaware of the ingredients in the best-selling Achtar drug, which is used to treat infantile spasms and often prescribed for more than a dozen other maladies.
The allegations were made by Rasvinder “Rose” Dhaliwal, a former associate director for market access, who was responsible for developing and maintaining relationships with commercial and government payers in the Northeast. She was hired just as Mallinckrodt bought Questor in 2014 and was fired in March 2018, according to her lawsuit, which was filed in federal court in New York this week.
About the Author Reprints
